Airing weekdays at 7:30 A.M. on

Airing weekdays at 7:30 A.M. on

iRULU’s Tablets For Children

High technology for kids at a low purchase price without sacrificing usability or functionality is not unheard of.  It’s all part of the latest developments in tablet technology from iRULU Technologies.  Join Director of Marketing, Elizabeth Little, as she demonstrates iRULU’s exciting and highly popular products, including the BabyPad, selling for sixty dollars. The BabyPad is a high-tech tablet geared to educate and help your young child. Don’t worry, it includes plenty of parental controls too for youe peace of mind.

The BabyPad is pre-loaded with mind stimulating applications made to help your child excel early on. iRULU brings parents an affordable tablet that can put responsible, controllable, intuitive educational technology right in the palm of your kids’ hands. Pre-loaded with mind-stimulating technology, it’s a great way for kinds to begin learning.

Besides the affordable price, the BabyPad differentiates itself with its’ exterior features designed specifically for kids. It is light weight and made of non-toxic materials. The tablet is safe in kids hands because of its’ rounded corners, it is rubberized to prevent injuries and scratched furniture and its’ tempered glass prevents fingerprints, smudges and glare. Most important, the BabyPad features parental control settings.

The interface was also made with kids in mind. It is really colorful and captivating and includes activities kids love such as painting and photo editing.

Make sure to visit iRULU.com because The Balancing Act viewers save  20%. Check out their other products too! iRULU is able to keep their products affordable because they sell direct to you, the consumer. Don’t wait shop, for the BabyPad and other great tablets now!

Health, Wealth, Beauty, and Business

Bringing the best tips from the experts in Atlanta in business, beauty, wealth management, child healthcare, car shopping, and more. Each year, Atlanta’s Women’s Entrepreneurship Initiative selects 15 local female entrepreneurs for a 15-month business training program. We meet women who have grown their companies, created jobs, and broke through the glass ceiling. With some […]

iMCD is the deadliest subtype of Castleman disease. Approximately one third of patients die within five years of diagnosis, and another third die within 10 years if not treated.

There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades.

Comments

comments